-Reuters
Cardiol Therapeutics Presented Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx For Recurrent Pericarditis; Administration Of CardiolRx Led To A Marked Reduction In The Primary Efficacy Endpoint Of Pericarditis Pain
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have
